Matches in Wikidata for { <http://www.wikidata.org/entity/Q92364141> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q92364141 description "article scientifique publié en 2019" @default.
- Q92364141 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q92364141 description "im März 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92364141 description "scientific article published on 15 March 2019" @default.
- Q92364141 description "wetenschappelijk artikel" @default.
- Q92364141 description "наукова стаття, опублікована 15 березня 2019" @default.
- Q92364141 name "Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1" @default.
- Q92364141 name "Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1" @default.
- Q92364141 type Item @default.
- Q92364141 label "Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1" @default.
- Q92364141 label "Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1" @default.
- Q92364141 prefLabel "Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1" @default.
- Q92364141 prefLabel "Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1" @default.
- Q92364141 P1433 Q92364141-62FC4743-08F6-49F1-9C4F-B98B211A689B @default.
- Q92364141 P1476 Q92364141-0707E108-CEF3-4132-A55C-37934C5C81AD @default.
- Q92364141 P2093 Q92364141-1B7E1872-6C0E-4CCA-A312-4C756746675D @default.
- Q92364141 P2093 Q92364141-28B52850-0D5B-486E-B488-80D594D18492 @default.
- Q92364141 P2093 Q92364141-58C25A44-0AE6-42BD-A41F-AD1A65FED839 @default.
- Q92364141 P2093 Q92364141-5A6FDD1C-80A8-4213-AF8A-AC3313A7FD7C @default.
- Q92364141 P2093 Q92364141-B75CC21D-51A7-4AFD-87FB-7288212E3787 @default.
- Q92364141 P2860 Q92364141-453B2863-4357-487A-9364-8B2345B0FA78 @default.
- Q92364141 P304 Q92364141-9D25314B-4CCA-43B5-B70C-8619AB3D6290 @default.
- Q92364141 P31 Q92364141-B59BD280-1044-4598-A348-D0417165B98B @default.
- Q92364141 P356 Q92364141-9C203F00-1AF8-46E0-8170-4B75A0D3C40E @default.
- Q92364141 P433 Q92364141-3DB70E1F-A34C-4031-A3AC-2F370E51C686 @default.
- Q92364141 P478 Q92364141-EE8AF763-DDB8-4B49-8C9F-6FDB5EC2D588 @default.
- Q92364141 P577 Q92364141-3FB6B60F-7E46-4832-A65A-03A40A082131 @default.
- Q92364141 P698 Q92364141-920B4DE6-0A16-4E04-BD22-51079037DD34 @default.
- Q92364141 P356 09168451.2019.1588096 @default.
- Q92364141 P698 30871430 @default.
- Q92364141 P1433 Q11192374 @default.
- Q92364141 P1476 "Protamine may have anti-atherogenic potential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1" @default.
- Q92364141 P2093 "Kenichi Hatanaka" @default.
- Q92364141 P2093 "Makoto Hasegawa" @default.
- Q92364141 P2093 "Masaki Okamoto" @default.
- Q92364141 P2093 "Shunichiro Kubota" @default.
- Q92364141 P2093 "Yukitoshi Takemura" @default.
- Q92364141 P2860 Q38829882 @default.
- Q92364141 P304 "1094-1101" @default.
- Q92364141 P31 Q13442814 @default.
- Q92364141 P356 "10.1080/09168451.2019.1588096" @default.
- Q92364141 P433 "6" @default.
- Q92364141 P478 "83" @default.
- Q92364141 P577 "2019-03-15T00:00:00Z" @default.
- Q92364141 P698 "30871430" @default.